#Japan #Tokyo #DNA Methylation #Keio University #Regenesome

New Patent on DNA Methylation Measurement by Regenesome and Keio University

In a remarkable collaborative effort, Regenesome Co., Ltd. has joined forces with Keio University and Gifu University to advance the study of DNA methylation. On July 9, 2026, this partnership jointly filed a patent for a novel method and a set of markers, aimed at efficiently measuring genome DNA methylation. The filed patent is titled "DNA Methylation Measurement Method Using Nanopore Sequencer and CpG Methylation Marker Set Obtained from the Method."

Understanding DNA Methylation and Its Importance

DNA methylation plays a critical role in epigenetics, where it regulates gene expression without altering the underlying genetic sequence. As it changes systematically with age, researchers have begun utilizing DNA methylation patterns as indicators of biological age – a concept known as the epigenetic clock. Until now, measuring methylation levels required costly and extensive analyses, limiting accessibility and practicality for broader applications. This new method promises to bridge that gap, providing an efficient, low-cost, and less invasive approach to measuring biological age.

Addressing the Challenges in Methylation Measurement

Traditionally, measuring DNA methylation has relied on high-cost and sophisticated technologies, which can deter widespread usage. The key advancements proposed in the patent include:
1. Targeting Specific Regions: Rather than analyzing the entire genome indiscriminately, the new method focuses on methylation-rich regions in CpG sites through effective preprocessing.
2. Simultaneous Measurement: The identified fragments will be analyzed using a compact nanopore sequencer, enabling normal sequencing and methylation state assessment concurrently.
3. Marker Set Definition: A specific set of CpG methylation markers will be introduced.

Together, these innovations provide a practical solution for efficiently measuring DNA methylation with minimal reliance on bulky, traditional equipment.

Potential Applications of the Technology

The implications of this technology extend beyond academic research, holding promise in preventive healthcare, particularly in aged healthcare and intervention efficacy evaluations. By measuring the state of DNA methylation before and after interventions – such as changes in diet or exercise – it will allow researchers and healthcare professionals to assess the biological impacts of these changes effectively.

Collaborative Research Institutions

This patent's success stems from the synergy between the research teams at Keio University’s Faculty of Pharmacy, Gifu University, and Regenesome Co., Ltd. By merging foundational research with practical business development insights, this collaboration stands as a significant milestone in the evolution of DNA methylation research.

Future Prospects

Regenesome is committed to elevating this patent into commercial success through the following avenues:

• - Rights Acquisition: Navigating domestic review processes while considering international patents under the PCT framework.
• - Technical Validation and Development: Focusing on applying the technology towards aging research, preventive healthcare, and evaluation of interventions.
• - Deepening Collaborations: Continuing partnerships with academic institutions for further research expansions
• - Researching Brain Age Measurement: Investigating biological age measurements particularly applicable to brain health, given its significance in aging.

About Regenesome Co., Ltd.

Regenesome aims to provide innovative solutions targeting aging suppression and regenerative medicine through nanoparticle technology. With a headquarters and research lab established in Takanawa Gateway City, the company accelerates its healthcare initiatives under its brand, "Saisei Lab," while gearing up for future medical field expansions.

For more information, visit Regenesome.

About SpaceSeed Holdings Co., Ltd.

SpaceSeed Holdings focuses on making science fiction a reality through investment, research, and entrepreneurial innovation, especially in deep-tech and longevity solutions. The company operates the "Fermentation and Longevity Fund," working to address societal challenges and develop technologies necessary for human habitation in space by 2040.

For more information, visit SpaceSeed Holdings.